Maternal floor infarction: Management of an underrecognized pathology

Journal of Obstetrics and Gynaecology Research

Volumn 40, Issue 1, 2014, Pages 293-296

  Al Sahan, Nada ^a   Grynspan, David ^b,c   Von Dadelszen, Peter ^e   Gruslin, Andrée ^a,d  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Diagnosis; Elevated a fetoprotein; Fetal growth restriction; Fibrin deposition; Globular placenta; Maternal floor infarction; Therapy

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA FETOPROTEIN; FOLIC ACID;

ADULT; ARTICLE; CASE REPORT; CESAREAN SECTION; ECHOGRAPHY; FEMALE; FIBRIN DEPOSITION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRAUTERINE GROWTH RETARDATION; MATERNAL FLOOR INFARCTION; OLIGOHYDRAMNIOS; PLACENTA DISORDER; PLACENTA PERFUSION; PREECLAMPSIA; PRENATAL SCREENING; PRIMIGRAVIDA; PROGNOSIS; RECURRENT DISEASE;

DIAGNOSIS; ELEVATED Α-FETOPROTEIN; FETAL GROWTH RESTRICTION; FIBRIN DEPOSITION; GLOBULAR PLACENTA; MATERNAL FLOOR INFARCTION; THERAPY;

ADULT; FEMALE; FETAL DEATH; FETAL GROWTH RETARDATION; FIBRIN; HUMANS; INFARCTION; PLACENTA; PLACENTAL CIRCULATION; PLACENTAL INSUFFICIENCY; PREGNANCY; RECURRENCE; SEVERITY OF ILLNESS INDEX; UP-REGULATION; UTERINE DISEASES;

EID: 84897030584     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/jog.12159     Document Type: Article

References (10)

1. Andres RL, Kuyper W, Resnik R, Piacquadio KM, Benirschke K. The association of maternal floor infarction of the placenta with adverse perinatal outcome. Am J Obstet Gynecol 1990; 163: 935-938.
2. Raspollini MR, Baczyk D, Kingdom JC, Viero S, Casper R, Keating S. Placental histopathologic features in patients with thrombophilic mutations. J Mater Fetal Neonatal Med 2007; 20: 113-123.
3. Gogia N, Machin GA. Maternal thrombophilias are associated with specific placental lesions. Pediatr Dev Pathol 2008; 11: 424-429.
4. Uxa R et al. Genetic polymorphisms in the fibrinolytic system of placentas with massive perivillous fibrin deposition. Placenta 2010; 31: 499-505.
5. Katzman PJ, Genest DR. Maternal floor infarction and massive perivillous fibrin deposition: Histological definitions, association with intrauterine fetal growth restriction, and risk of recurrence. Pediatric and Developmental. Pathology 2002; 5: 159-164.
6. Adams-Chapman I, Vaucher YE, Bejar RF, Benirschke K, Baergen RN, Moore TR. Maternal floor infarction of the placenta: Association with central nervous system injury and adverse neurodevelopmental outcome. J Perinatol 2002; 22: 236-241.
7. von Dadelszen P, Dwinnell S, Magee LA et al. Sildenafil citrate therapy for severe early-onset intrauterine growth restriction. BJOG 2011; 118: 624-628.
8. Sebire NJ, Backos M, Goldin RD, Regan L. Placental massive perivillous fibrin deposition associated with antiphospholipid antibody syndrome. BJOG 2002; 109: 570-573.
9. Makino A, Suzuki Y, Yamamoto T, Sato T, Kojima K, Suzumori K. Use of aspirin and low-molecular-weight heparin to prevent recurrence of maternal floor infarction in women without evidence of antiphospholipid antibody syndrome. Fetal Diagn Ther 2004; 19: 261-265.
10. Chang P, Suzuki Y, Yamamoto T, Sato T, Kojima K, Suzumori K. Intravenous immunoglobulin in antiphospholipid syndrome and maternal floor infarction when standard treatment fails: A case report. Am J Perinatology 2006; 23: 125-129.